In summary, our data suggest that selective antagonism of TNFR1 using an inhaled dAb may offer therapeutic benefit in patients with ARDS, a common and devastating condition that currently has no effective disease-modifying therapy. The gene discussed is TNFRSF1A; the disease is acute respiratory distress syndrome.